BACKGROUND: Because immune responses within the tumor microenvironment are important predictors of tumor biology, correlations of types of tumor infiltrating lymphocytes (TILs) with clinical outcomes were determined in 278 patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Infiltrating levels of CD4 (helper T cells), CD8 (cytotoxic/suppressor T cells), FoxP3 (regulatory T cells), CD68 (myeloid-derived suppressor cells,) and CD1a (Langerhans) cells were measured in tissue microarrays (TMAs). Cox models tested associations with patient outcomes after adjusting for all known prognostic factors. Median follow-up was 36.6 months. RESULTS: Higher CD4 and CD8 TIL levels were associated with improved overall survival (OS; hazard ratio [HR] = 0.77; 95% confidence interval [CI] = 0.65-0.93; p = .005 and HR = 0.77; 95% CI = 0.64-0.94; p = .008, respectively), and relapse-free survival (RFS; p = .03 and .05, respectively). After controlling for prognostic factors, higher CD4 levels predicted improved OS and disease-specific survival (DSS; p = .003 and p = .004, respectively). CONCLUSION: The findings suggest that TILs are a significant independent prognostic factor for HNSCC that differ by treatment.
BACKGROUND: Because immune responses within the tumor microenvironment are important predictors of tumor biology, correlations of types of tumor infiltrating lymphocytes (TILs) with clinical outcomes were determined in 278 patients with head and neck squamous cell carcinoma (HNSCC). METHODS: Infiltrating levels of CD4 (helper T cells), CD8 (cytotoxic/suppressor T cells), FoxP3 (regulatory T cells), CD68 (myeloid-derived suppressor cells,) and CD1a (Langerhans) cells were measured in tissue microarrays (TMAs). Cox models tested associations with patient outcomes after adjusting for all known prognostic factors. Median follow-up was 36.6 months. RESULTS: Higher CD4 and CD8 TIL levels were associated with improved overall survival (OS; hazard ratio [HR] = 0.77; 95% confidence interval [CI] = 0.65-0.93; p = .005 and HR = 0.77; 95% CI = 0.64-0.94; p = .008, respectively), and relapse-free survival (RFS; p = .03 and .05, respectively). After controlling for prognostic factors, higher CD4 levels predicted improved OS and disease-specific survival (DSS; p = .003 and p = .004, respectively). CONCLUSION: The findings suggest that TILs are a significant independent prognostic factor for HNSCC that differ by treatment.
Authors: Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green Journal: J Clin Oncol Date: 2011-04-11 Impact factor: 44.544
Authors: Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden Journal: Cancer Immunol Immunother Date: 2011-11-06 Impact factor: 6.968
Authors: Qiao Li; Xiangming Lao; Qin Pan; Ning Ning; Ji Yet; Yingxin Xu; Shengping Li; Alfred E Chang Journal: Clin Cancer Res Date: 2011-06-20 Impact factor: 12.531
Authors: Carol R Bradford; Bhavna Kumar; Emily Bellile; Julia Lee; Jeremy Taylor; Nisha D'Silva; Kitrina Cordell; Celina Kleer; Robbi Kupfer; Pawan Kumar; Susan Urba; Francis Worden; Avraham Eisbruch; Gregory T Wolf; Theodoros N Teknos; Mark E P Prince; Douglas B Chepeha; Norman D Hogikyan; Jeffrey S Moyer; Thomas E Carey Journal: Laryngoscope Date: 2013-07-12 Impact factor: 3.325
Authors: Cecilia Nordfors; Nathalie Grün; Nikolaos Tertipis; Andreas Ährlund-Richter; Linnea Haeggblom; Lars Sivars; Juan Du; Tommy Nyberg; Linda Marklund; Eva Munck-Wikland; Anders Näsman; Torbjörn Ramqvist; Tina Dalianis Journal: Eur J Cancer Date: 2013-04-06 Impact factor: 9.162
Authors: Gregory T Wolf; William Winter; Emily Bellile; Ariane Nguyen; C R Donnelly; Jonathan B McHugh; Dafydd Thomas; Lahin Amlani; Laura Rozek; Yu L Lei Journal: Oral Oncol Date: 2018-10-22 Impact factor: 5.337
Authors: Yu Lei; Yuying Xie; Yee Sun Tan; Mark E Prince; Jeffrey S Moyer; Jacques Nör; Gregory T Wolf Journal: Oral Oncol Date: 2016-08-21 Impact factor: 5.337
Authors: Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Oral Oncol Date: 2017-12-23 Impact factor: 5.337
Authors: Lada A Koneva; Yanxiao Zhang; Shama Virani; Pelle B Hall; Jonathan B McHugh; Douglas B Chepeha; Gregory T Wolf; Thomas E Carey; Laura S Rozek; Maureen A Sartor Journal: Mol Cancer Res Date: 2017-09-19 Impact factor: 5.852
Authors: Diana Groza; Sebastian Gehrig; Pavol Kudela; Martin Holcmann; Christine Pirker; Carina Dinhof; Hemma H Schueffl; Marek Sramko; Julia Hoebart; Fatih Alioglu; Michael Grusch; Manfred Ogris; Werner Lubitz; Bernhard K Keppler; Irena Pashkunova-Martic; Christian R Kowol; Maria Sibilia; Walter Berger; Petra Heffeter Journal: Oncoimmunology Date: 2018-02-16 Impact factor: 8.110
Authors: Eva B Yokosawa; Anna E Arthur; Katie M Rentschler; Gregory T Wolf; Laura S Rozek; Alison M Mondul Journal: Laryngoscope Date: 2018-05-14 Impact factor: 3.325